Conn's Current Therapy 2023 RD Kellerman, DP Rakel Elsevier Health Sciences, 2022 | 55 | 2022 |
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma TJ Phillips, AJ Olszewski, J Munoz, TM Kim, DH Yoon, R Greil, J Westin, ... BLOOD 136, 2020 | 44 | 2020 |
Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1 Z Xu, HHSK Potula, A Vallurupalli, D Perry, H Baker, BP Croker, ... The Journal of Immunology 186 (12), 6673-6682, 2011 | 38 | 2011 |
Conn's current therapy 2019 RD Kellerman, D Rakel Elsevier Health Sciences, 2018 | 34* | 2018 |
A New Zealand Black-derived locus suppresses chronic graft-versus-host disease and autoantibody production through nonlymphoid bone marrow-derived cells Z Xu, A Vallurupalli, C Fuhrman, D Ostrov, L Morel The Journal of Immunology 186 (7), 4130-4139, 2011 | 29 | 2011 |
Randomized Phase II/III Study of DA-EPOCH-R+/-Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701 JS Abramson, AS Ruppert, S Giri, A Hudson, ED Hsi, RF Little, SD Gore, ... Blood 138, 523, 2021 | 21 | 2021 |
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells PH Vekaria, A Kumar, D Subramaniam, N Dunavin, A Vallurupalli, ... Leukemia 33 (7), 1675-1686, 2019 | 13 | 2019 |
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies GP Collins, TN Clevenger, KA Burke, B Yang, A MacDonald, ... Leukemia & Lymphoma 62 (11), 2625-2636, 2021 | 5 | 2021 |
Fractionated dosing of CLR 131 in patients with relapsed or refractory multiple myeloma (RRMM) S Ailawadhi, PJ Stiff, E Ibrahim, A Vallurupalli, EH Cull, DJ Green, K Oliver, ... Blood 134, 144, 2019 | 4 | 2019 |
A Diverse Spectrum of Immune Complex–and Complement-Mediated Kidney Diseases Is Associated With Mantle Cell Lymphoma NK Andeen, S Abdulameer, V Charu, JE Zuckerman, M Troxell, ... Kidney international reports 7 (3), 568-579, 2022 | 3 | 2022 |
Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma T Banerjee, A Vallurupalli Current Problems in Cancer 46 (1), 100825, 2022 | 3 | 2022 |
A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas. P Porcu, B Haverkos, E Brem, A Vallurupalli, T Feldman, O Alpdogan, ... Journal of Clinical Oncology 37 (15_suppl), 7551-7551, 2019 | 3 | 2019 |
Functional characterization of NPM1-TYK2 fusion oncogene BR 4. Kuravi S, Baker RW, Mushtaq MU, Saadi I, Lin TL, Vivian CJ ... NPJ Precision Oncology 6 (1), 2022 | 2 | 2022 |
A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma T Banerjee, M Newman, A Chen, RT Maziarz, L Schachter, SE Spurgeon, ... Leukemia & Lymphoma, 1-4, 2023 | 1 | 2023 |
Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell … U Greenbaum, H Hashmi, M Elsawy, S Kim, A Moskop, FT Awan, ... Blood 140 (Supplement 1), 4636-4638, 2022 | 1 | 2022 |
ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL) LE Budde, A Vallurupalli, S Babu, IS Lossos, JP Alderuccio, JC Chavez, ... Hematological Oncology 37, 564-566, 2019 | 1 | 2019 |
CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas S Kuravi, E Parrott, S Ganguly, A Vallurupalli, Y Saunthararajah, BS Blagg, ... Blood 130, 2758, 2017 | 1 | 2017 |
Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell … PR Geethakumari, K Wudhikarn, MD Jain, A Vallurupalli, S Kim, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCL. G Manu, A Vallurupalli, S Williamson, J Brower, V Bachanova, JP McGuirk, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R … P Porcu, BM Haverkos, O Alpdogan, M Capra, TA Feldman, E Brem, ... Blood 134, 465, 2019 | | 2019 |